Business News • PR NewsWire • Genomic Health and Epic Sciences Announce Strategic Collaboration to Deliver Novel AR-V7 Liquid Biopsy Test to Predict Treatment Response in Metastatic Prostate Cancer

Genomic Health and Epic Sciences Announce Strategic Collaboration to Deliver Novel AR-V7 Liquid Biopsy Test to Predict Treatment Response in Metastatic Prostate Cancer

Genomic Health and Epic Sciences Announce Strategic Collaboration to Deliver Novel AR-V7 Liquid Biopsy Test to Predict Treatment Response in Metastatic Prostate Cancer

REDWOOD CITY, Calif. and SAN DIEGO, July 7, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) and Epic Sciences, Inc. today announced an exclusive agreement to commercialize Epic Sciences' novel AR-V7 liquid biopsy test in the United States through Genomic Health's world-class...

View More : http://www.prnewswire.com/news-releases/genomic-health-and-epic-sciences-announce-strategic-collaboration-to-deliver-nov...

Releted News by prnewswire

Hiring in the Back Half of 2016 is Expected to Look a Lot Like 2015, But With Better Wages

U.S. Census Bureau Daily Feature for July 7: Cutting Things Fine